Abstract
Background Diabetes is the leading cause of kidney disease, and heritability studies demonstrate a substantial, yet poorly understood, contribution of genetics to kidney complications in people with diabetes.
Methods We performed genome-wide association study (GWAS) meta-analyses using ten different phenotypic definitions of diabetic kidney disease (DKD), including nearly 27,000 individuals with diabetes, and integrated the results with various kidney omics datasets.
Results The meta-analysis identified a novel low frequency intronic variant (rs72831309) in the TENM2 gene encoding teneurin transmembrane protein 2 associated with a lower risk of the combined chronic kidney disease (CKD; eGFR<60 ml/min/1.73 m2) and DKD (microalbuminuria or worse) phenotype (“CKD-DKD”, odds ratio 2.08, p=9.8×10−9). Gene-level analysis identified ten genes associated with DKD (COL20A1, DCLK1, EIF4E, PTPRN-RESP18, GPR158, INIP-SNX30, LSM14A, and MFF, p<2.7×10−6). Integration of GWAS data with human glomerular and tubular expression data in a transcriptome-wide association study demonstrated higher tubular AKIRIN2 gene expression in DKD versus non-DKD controls (p=1.1×10−6). The lead SNPs within the DCLK1, AKIRIN2, SNX30 and three other gene regions significantly alterated the methylation at this region in kidneys (p<2.2×10−11). Expression of target genes in kidney tubules or glomeruli correlated with relevant pathological phenotypes. For example, tubular TENM2 expression positively correlated with eGFR (p=2.3×10−9) and negatively with tubulointerstitial fibrosis (p=4.7×10−9), tubular DCLK1 expression positively correlated with fibrosis (p=1.6×10−12), and SNX30 level positively correlated with eGFR (p=7.6×10−13) and negatively with fibrosis (p<2×10−16).
Conclusions GWAS meta-analysis and integration with renal omics data points to novel genes contributing to pathogenesis of DKD.
Competing Interest Statement
P-H.G. reports receiving lecture honorariums from Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Medscape, MSD, Mundipharma, Novo Nordisk, PeerVoice, Sanofi, SCIARC and being an advisory board member of Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elo Water, Medscape, MSD, Mundipharma, Nestle, Novo Nordisk, PeerVoice, Sanofi and Sciarc. J.C.F. has received speaking honoraria from AstraZeneca, Merck and Novo Nordisk for scientific talks over which he had full control of content.
Funding Statement
This study was funded by JDRF (grants S-SRA-2014-276-Q-R and 17-2013-7), and NIDDK R01 DK105154. Research in FinnDiane was supported by Folkhälsan Research Foundation, Wilhelm and Else Stockmann Foundation, “Liv och Hälsa” Society, Helsinki University Central Hospital Research Funds (EVO TYH2018207), Academy of Finland (299200 and 316664), and Novo Nordisk Foundation (NNF OC0013659). Acquisition of clinical data and samples from the Pima Indians was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases and by the American Diabetes Association (Clinical Science Award 1-08-CR-42). JBC was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (K99DK127196). EA was funded by grants from the Swedish Research Council (2017-02688, 2020-02191) and the Novo Nordisk foundation (NNF18OC0034408).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nephrectomy samples: The study was approved by the institutional review board of the University of Pennsylvania. Pima Indian cohort study was approved by the Institutional Review Board of the National Institute of Diabetes and Digestive and Kidney Diseases.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The GWAS meta-analysis results can be accessed via the T1D, T2D, and Cardiometabolic Disease (CMD) Knowledge Portals (https://t1d.hugeamp.org/; https://t2d.hugeamp.org/; https://hugeamp.org/), and downloaded on their respective downloads pages.
